Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy of a New Formulation of Bimatoprost/Timolol Ophthalmic Solution Compared With Bimatoprost/Timolol Ophthalmic Solution in Patients With Glaucoma or Ocular Hypertension

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patient has ocular hypertension or glaucoma in both eyes~* Requires IOP-lowering therapy in each eye~Exclusion Criteria:~* Active or recurrent eye disease that would interfere with interpretation of study data in either eye~* History of any eye surgery or laser in either eye within 6 months~* Required chronic use of other eye medications during the study~* Anticipated wearing of contact lenses during the study.~* Intermittent use of oral, intramuscular, or intravenous corticosteroids within 21 days

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- bimatoprost/timolol formulation A (Type: EXPERIMENTAL): One drop of bimatoprost/timolol formulation A fixed combination ophthalmic solution administered in each eye every morning for 12 weeks.
- bimatoprost/timolol fixed combination ophthalmic solution (Type: ACTIVE_COMPARATOR): One drop of bimatoprost 0.03%/timolol 0.5% fixed combination ophthalmic solution (Ganfort®) administered in each eye every morning for 12 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).